An agent run, visualized

{"query": "IDH1"}

{"query": "IDH1", "total": 3, "targets": [{"ensembl_id": "ENSG00000138413", "symbol": "IDH1", "name": "isocitrate dehydrogenase (NADP(+)) 1", "biotype": "protein_coding", "description": "isocitrate dehydrogenase (NADP(+)) 1"}, {"ensembl_id": "ENSG00000231908", "symbol": "IDH1-AS1", "name": "IDH1 antisense RNA 1", "biotype": "lncRNA", "description": "IDH1 antisense RNA 1"}, {"ensembl_id": "ENSG00000234115", "symbol": "IDH1P1", "name": "IDH1 pseudogene 1", "biotype": "processed_pseudogene", "description": "IDH1 pseudogene 1"}], "source": {"api": "Open Targets Platform GraphQL API", "url": "https://api.platform.opentargets.org/api/v4/graphql", "retrieved": "2026-09-19"}}

[saved as work/target-biologist/0001-search_target.json ; cite this path, with an exact quote, as evidence]

{"ensembl_id": "ENSG00000138413", "limit": 25}

{"ensembl_id": "ENSG00000138413", "symbol": "IDH1", "total_associations": 827, "limit": 25, "associations": [{"disease_id": "MONDO_0018874", "disease": "acute myeloid leukemia", "score": 0.7788, "datatype_scores": {"clinical": 0.9315, "affected_pathway": 0.8275, "literature": 0.9918, "genetic_association": 0.5593, "somatic_mutation": 0.7758}}, {"disease_id": "MONDO_0018177", "disease": "glioblastoma", "score": 0.6574, "datatype_scores": {"literature": 0.9973, "affected_pathway": 0.6079, "rna_expression": 0.1084, "somatic_mutation": 0.7936}}, {"disease_id": "MONDO_0019087", "disease": "cholangiocarcinoma", "score": 0.6519, "datatype_scores": {"clinical": 0.7984, "affected_pathway": 0.6079, "literature": 0.9172, "genetic_association": 0, "somatic_mutation": 0.8275}}, {"disease_id": "MONDO_0021042", "disease": "glioma", "score": 0.6368, "datatype_scores": {"clinical": 0.801, "genetic_literature": 0.6079, "affected_pathway": 0.6079, "literature": 0.9986, "somatic_mutation": 0.6079}}, {"disease_id": "MONDO_0013808", "disease": "Maffucci syndrome", "score": 0.6309, "datatype_scores": {"literature": 0.4606, "genetic_association": 0.2432, "somatic_mutation": 0.7207, "genetic_literature": 0.8248}}, {"disease_id": "Orphanet_296", "disease": "Enchondromatosis", "score": 0.6285, "datatype_scores": {"literature": 0.1274, "genetic_association": 0.7859, "somatic_mutation": 0.5593, "genetic_literature": 0.7367}}, {"disease_id": "MONDO_0019781", "disease": "astrocytoma (excluding glioblastoma)", "score": 0.5887, "datatype_scores": {"literature": 0.9956, "rna_expression": 0.0787, "somatic_mutation": 0.6079, "clinical": 0.7932}}, {"disease_id": "MONDO_0016695", "disease": "oligodendroglioma", "score": 0.5787, "datatype_scores": {"literature": 0.9848, "rna_expression": 0.0759, "somatic_mutation": 0.4559, "clinical": 0.815}}, {"disease_id": "MONDO_0013941", "disease": "metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria", "score": 0.5494, "datatype_scores": {"literature": 0.0182, "genetic_association": 0.5593, "genetic_literature": 0.7635}}, {"disease_id": "MONDO_0008145", "disease": "Ollier disease", "score": 0.5213, "datatype_scores": {"literature": 0.2665, "genetic_literature": 0.8442}}, {"disease_id": "MONDO_0021637", "disease": "low grade glioma", "score": 0.4835, "datatype_scores": {"literature": 0.1318, "somatic_mutation": 0.7599, "clinical": 0.1299}}, {"disease_id": "MONDO_0024498", "disease": "glioma susceptibility 1", "score": 0.4751, "datatype_scores": {"genetic_association": 0.6417, "somatic_mutation": 0.5593}}, {"disease_id": "MONDO_0015667", "disease": "acute myeloid leukemia by FAB classification", "score": 0.4684, "datatype_scores": {"clinical": 0.7705}}, {"disease_id": "MONDO_0005105", "disease": "melanoma", "score": 0.4483, "datatype_scores": {"literature": 0.6981, "genetic_association": 0, "somatic_mutation": 0.5775}}, {"disease_id": "MONDO_0016691", "disease": "pilocytic astrocytoma", "score": 0.4431, "datatype_scores": {"literature": 0.3116, "somatic_mutation": 0.5775}}, {"disease_id": "MONDO_0005012", "disease": "cutaneous melanoma", "score": 0.44, "datatype_scores": {"literature": 0.0849, "somatic_mutation": 0.5775}}, {"disease_id": "MONDO_0018881", "disease": "myelodysplastic syndrome", "score": 0.4282, "datatype_scores": {"literature": 0.8645, "somatic_mutation": 0.4559, "clinical": 0.5712}}, {"disease_id": "MONDO_0009807", "disease": "osteosarcoma", "score": 0.4267, "datatype_scores": {"literature": 0.8094, "somatic_mutation": 0.5471}}, {"disease_id": "MONDO_0005082", "disease": "prostate adenocarcinoma", "score": 0.4264, "datatype_scores": {"literature": 0.671, "somatic_mutation": 0.5492}}, {"disease_id": "MONDO_0007256", "disease": "hepatocellular carcinoma", "score": 0.4142, "datatype_scores": {"literature": 0.8353, "rna_expression": 0.0434, "genetic_association": 0, "somatic_mutation": 0.5298}}, {"disease_id": "MONDO_0008977", "disease": "chondrosarcoma", "score": 0.4091, "datatype_scores": {"literature": 0.9...[truncated 967 chars]

{"ensembl_id": "ENSG00000138413"}

{"ensembl_id": "ENSG00000138413", "symbol": "IDH1", "tractability": {"SM": {"positive": ["Approved Drug", "Structure with Ligand", "High-Quality Ligand", "High-Quality Pocket"], "negative": ["Advanced Clinical", "Phase 1 Clinical", "Med-Quality Pocket", "Druggable Family"]}, "AB": {"positive": ["GO CC high conf"], "negative": ["Approved Drug", "Advanced Clinical", "Phase 1 Clinical", "UniProt loc high conf", "UniProt loc med conf", "UniProt SigP or TMHMM", "GO CC med conf", "Human Protein Atlas loc"]}, "PR": {"positive": ["Database Ubiquitination", "Half-life Data", "Small Molecule Binder"], "negative": ["Approved Drug", "Advanced Clinical", "Phase 1 Clinical", "Literature", "UniProt Ubiquitination"]}, "OC": {"positive": [], "negative": ["Approved Drug", "Advanced Clinical", "Phase 1 Clinical"]}}, "note": "modalities: SM small molecule, AB antibody, PR PROTAC, OC other clinical", "source": {"api": "Open Targets Platform GraphQL API", "url": "https://api.platform.opentargets.org/api/v4/graphql", "retrieved": "2026-09-19"}}

[saved as work/target-biologist/0003-target_tractability.json ; cite this path, with an exact quote, as evidence]

{"ensembl_id": "ENSG00000138413", "limit": 25}

{"ensembl_id": "ENSG00000138413", "symbol": "IDH1", "total_drugs": 8, "limit": 25, "drugs": [{"drug_id": "CHEMBL4297610", "drug": "OLUTASIDENIB", "drug_type": "Small molecule", "mechanism": ["Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor"], "phase": "APPROVAL", "status": {"UNKNOWN": 5, "RECRUITING": 10, "WITHDRAWN": 2, "NOT_YET_RECRUITING": 3, "COMPLETED": 2}, "diseases": [{"id": "MONDO_0015667", "name": "acute myeloid leukemia by FAB classification"}, {"id": "MONDO_0018874", "name": "acute myeloid leukemia"}, {"id": "MONDO_0018881", "name": "myelodysplastic syndrome"}, {"id": "MONDO_0006033", "name": "diffuse intrinsic pontine glioma"}, {"id": "MONDO_0100342", "name": "malignant glioma"}, {"id": null, "name": "clonal cytopenia of undetermined significance"}, {"id": "MONDO_0018881", "name": "myelodysplastic syndrome"}, {"id": "MONDO_0020311", "name": "chronic myelomonocytic leukemia"}], "disease_count": 16}, {"drug_id": "CHEMBL3989958", "drug": "IVOSIDENIB", "drug_type": "Small molecule", "mechanism": ["Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor"], "phase": "APPROVAL", "status": {"UNKNOWN": 10, "APPROVED_FOR_MARKETING": 1, "COMPLETED": 7, "ACTIVE_NOT_RECRUITING": 11, "RECRUITING": 27, "WITHDRAWN": 3, "NOT_YET_RECRUITING": 3, "TERMINATED": 2}, "diseases": [{"id": null, "name": ""}, {"id": "MONDO_0018874", "name": "acute myeloid leukemia"}, {"id": "MONDO_0015667", "name": "acute myeloid leukemia by FAB classification"}, {"id": "MONDO_0019087", "name": "cholangiocarcinoma"}, {"id": null, "name": "acute myeloid leukemia with an IDH1 mutation"}, {"id": "MONDO_0018881", "name": "myelodysplastic syndrome"}, {"id": null, "name": "biliary cancer"}, {"id": null, "name": "conventional chondrosarcoma"}], "disease_count": 36}, {"drug_id": "CHEMBL4279047", "drug": "VORASIDENIB", "drug_type": "Small molecule", "mechanism": ["IDH1/IDH2 inhibitor", "Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor", "Isocitrate dehydrogenase [NADP], mitochondrial inhibitor"], "phase": "APPROVAL", "status": {"UNKNOWN": 5, "APPROVED_FOR_MARKETING": 1, "ACTIVE_NOT_RECRUITING": 4, "RECRUITING": 4, "NOT_YET_RECRUITING": 4, "COMPLETED": 3}, "diseases": [{"id": "MONDO_0019781", "name": "astrocytoma (excluding glioblastoma)"}, {"id": "MONDO_0016695", "name": "oligodendroglioma"}, {"id": "MONDO_0021042", "name": "glioma"}, {"id": null, "name": "isocitrate dehydrogenase 2 mutation"}, {"id": null, "name": "isocitrate dehydrogenase 1 mutation"}, {"id": "MONDO_0015667", "name": "acute myeloid leukemia by FAB classification"}, {"id": "MONDO_0044881", "name": "hematopoietic and lymphoid cell neoplasm"}, {"id": "MONDO_0000448", "name": "paraganglioma"}], "disease_count": 12}, {"drug_id": "CHEMBL4651002", "drug": "SAFUSIDENIB", "drug_type": "Small molecule", "mechanism": ["Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor"], "phase": "PHASE_3", "status": {"RECRUITING": 1, "COMPLETED": 1, "UNKNOWN": 1}, "diseases": [{"id": "MONDO_0019781", "name": "astrocytoma (excluding glioblastoma)"}, {"id": "MONDO_0016695", "name": "oligodendroglioma"}, {"id": "MONDO_0000448", "name": "paraganglioma"}, {"id": "MONDO_0021637", "name": "low grade glioma"}, {"id": "MONDO_0021042", "name": "glioma"}, {"id": "MONDO_0005070", "name": "neoplasm"}], "disease_count": 6}, {"drug_id": "CHEMBL4650282", "drug": "DS-1001B", "drug_type": "Small molecule", "mechanism": ["Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor"], "phase": "PHASE_2", "status": {"ACTIVE_NOT_RECRUITING": 2}, "diseases": [{"id": "MONDO_0021042", "name": "glioma"}], "disease_count": 1}, {"drug_id": "CHEMBL4167360", "drug": "IDH305", "drug_type": "Small molecule", "mechanism": ["Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor"], "phase": "PHASE_2", "status": {"WITHDRAWN": 3, "UNKNOWN": 1, "ACTIVE_NOT_RECRUITING": 1}, "diseases": [{"id": "MONDO_0000448", "name": "paraganglioma"}, {"id": "MONDO_0021637", "name": "low grade glioma"}, {"id": null, "name": "advanced malignancy"}, {"id": "MONDO_0018874",...[truncated 1203 chars]

{"condition": "IDH1-mutant glioma", "intervention": "IDH inhibitor", "limit": 25}

{"total_count": 1, "returned": 1, "limit": 25, "trials": [{"nct_id": "NCT03749187", "title": "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE1"], "study_type": "INTERVENTIONAL", "sponsor": "University of California, San Francisco", "enrollment": 78, "enrollment_type": "ESTIMATED", "start_date": "2019-04-03", "primary_completion_date": "2026-06-30", "completion_date": "2029-07-30", "conditions": ["Glioblastoma", "IDH1 Gene Mutation", "IDH2 Gene Mutation", "Low Grade Glioma", "Malignant Glioma", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma", "WHO Grade II Glioma", "WHO Grade III Glioma"], "interventions": ["DRUG: PARP Inhibitor BGB-290", "DRUG: Temozolomide (TMZ)"], "primary_outcomes": [{"measure": "Proportion of participants with Dose Limiting Toxicities (DLTs)", "time_frame": "Up to 28 days"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT03749187"}], "source": {"api": "ClinicalTrials.gov API v2", "url": "https://clinicaltrials.gov/api/v2/studies", "retrieved": "2026-09-19"}}

[saved as work/clinical-trialist/0001-search_trials.json ; cite this path, with an exact quote, as evidence]

{"intervention": "vorasidenib", "condition": "IDH1-mutant glioma", "limit": 25}

{"total_count": 7, "returned": 7, "limit": 25, "trials": [{"nct_id": "NCT07703436", "title": "Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease", "status": "NOT_YET_RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Nuvation Bio Inc.", "enrollment": 40, "enrollment_type": "ESTIMATED", "start_date": "2027-03", "primary_completion_date": "2030-09", "completion_date": "2032-03", "conditions": ["Grade 2 IDH1-mutant Glioma", "Grade 3 IDH1-mutant Glioma", "Glioma", "IDH1-mutant Glioma", "Oligodendroglioma", "Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted", "Astrocytoma IDH Mutant Grade 3", "Astrocytoma IDH Mutant Grade 2"], "interventions": ["DRUG: Safusidenib"], "primary_outcomes": [{"measure": "Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)", "time_frame": "From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT07703436"}, {"nct_id": "NCT06780930", "title": "Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE3"], "study_type": "INTERVENTIONAL", "sponsor": "Servier", "enrollment": 57, "enrollment_type": "ACTUAL", "start_date": "2024-10-18", "primary_completion_date": "2026-05-07", "completion_date": "2030-10-31", "conditions": ["Residual or Recurrent Grade 2 IDH Mutant Glioma"], "interventions": ["DRUG: Vorasidenib", "DRUG: Placebo"], "primary_outcomes": [{"measure": "Progression-Free Survival (PFS)", "time_frame": "Approximately 1.5 years"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT06780930"}, {"nct_id": "NCT06478212", "title": "Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE1", "PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Institut de Recherches Internationales Servier", "enrollment": 51, "enrollment_type": "ACTUAL", "start_date": "2025-01-22", "primary_completion_date": "2027-11", "completion_date": "2028-06", "conditions": ["IDH1-mutant Glioma", "IDH2-mutant Glioma"], "interventions": ["DRUG: Vorasidenib", "DRUG: Temozolomide (TMZ)"], "primary_outcomes": [{"measure": "Phase 1b ONLY: Dose-limiting toxicities (DLTs)", "time_frame": "Through cycle 1 (each cycle is 28 days)"}, {"measure": "Number and severity of adverse events (AEs), serious adverse events (SAEs), and AEs of special interest (AESIs)", "time_frame": "Through 30 days after the end of treatment (Approximately 3 years)"}, {"measure": "Progression-free Survival (PFS) status at 12 months", "time_frame": "12 months after treatment initiation"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT06478212"}, {"nct_id": "NCT05609994", "title": "ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas", "status": "RECRUITING", "phase": ["PHASE1"], "study_type": "INTERVENTIONAL", "sponsor": "Katy Peters, MD, PhD", "enrollment": 48, "enrollment_type": "ESTIMATED", "start_date": "2025-07-15", "primary_completion_date": "2027-08", "completion_date": "2029-08", "conditions": ["Low Grade Glioma of Brain"], "interventions": ["DRUG: PEPIDH1M vaccine + vorasidenib"], "primary_outcomes": [{"measure": "To assess the safety of the PEPIDH1M vaccine in combination vorasidenib in adult patients with progressive IDH1 mutant World Health Organization (WHO) Grade 2-3 gliomas", "time_frame": "3.5 years"}, {"measure": "Describe the efficacy, as measured by progression-free survival (PFS), of the combination of PEPIDH1M vaccine and vorasidenib in adult...[truncated 3183 chars]

{"intervention": "ivosidenib", "condition": "glioma"}

{"total_count": 6, "returned": 6, "limit": 10, "trials": [{"nct_id": "NCT03343197", "title": "Study of AG-120 and AG-881 in Subjects With Low Grade Glioma", "status": "COMPLETED", "phase": ["PHASE1"], "study_type": "INTERVENTIONAL", "sponsor": "Institut de Recherches Internationales Servier", "enrollment": 49, "enrollment_type": "ACTUAL", "start_date": "2018-03-20", "primary_completion_date": "2019-08-02", "completion_date": "2025-03-28", "conditions": ["Glioma"], "interventions": ["DRUG: AG-120", "DRUG: AG881"], "primary_outcomes": [{"measure": "2-HG concentration in surgically resected tumors", "time_frame": "Up to 4 weeks, on average"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT03343197"}, {"nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "National Cancer Institute (NCI)", "enrollment": 1377, "enrollment_type": "ACTUAL", "start_date": "2017-07-31", "primary_completion_date": "2025-03-31", "completion_date": "2027-01-06", "conditions": ["Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma"], "interventions": ["PROCEDURE: Biopsy Procedure", "PROCEDURE: Biospecimen Collection", "PROCEDURE: Bone Marrow Aspiration and Biopsy", "PROCEDURE: Bone Scan", "PROCEDURE: Computed Tomography", "DRUG: Ensartinib", "DRUG: Erdafitinib", "DRUG: Ivosidenib", "OTHER: Laboratory Biomarker Analysis", "DRUG: Larotrectinib Sulfate"], "primary_outcomes": [{"measure": "Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs", "time_frame": "Up to 2 years from study entry"}], "why_stopped": null, "has_results": true, "url": "https://clinicaltrials.gov/study/NCT03155620"}, {"nct_id": "NCT04195555", "title": "Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "National Cancer Institute (NCI)", "enrollment": 3, "enrollment_type": "ACTUAL", "start_date": "2020-07-20", "primary_completion_date": "2025-03-31", "completion_date": "2027-05-09", "conditions": ["Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma"], "interventions": ["DRUG: Ivosidenib"], "primary_outcomes": [{"measure": "Objective Response Rate (ORR; Complete Response + Partial Response) in Pediatric Patients Treated With Ivosidenib", "time_frame": "Up to 2 years from study entry"}], "why_stopped": null, "has_results": true, "url": "https://clinicaltrials.gov/study/NCT04195555"}, {"nct_id": "NCT06648473", "title": "Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib", "status": "WITHDRAWN", "phase": ["NA"], "study_type": "INTERVENTIONAL", "sponsor": "Duke University", "enrollment": 0, "enrollment_type": "ACTUAL", "start_date": "2026-01-01", "primary_completion_date": "2027-12-01", "completion_date": "2027-12-01", "conditions": ["Low Grade Glioma of Brain"], "interventions": ["DIAGNOSTIC_TEST: MRI Scan"], "primary_outcomes": [{"measure": "Repeatability", "time_frame": "1 year"}], "why_stopped": "sponsor withdrew funding", "has_r...[truncated 2095 chars]

{"intervention": "olutasidenib", "condition": "glioma"}

{"total_count": 3, "returned": 3, "limit": 10, "trials": [{"nct_id": "NCT03684811", "title": "A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation", "status": "COMPLETED", "phase": ["PHASE1", "PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Forma Therapeutics, Inc.", "enrollment": 93, "enrollment_type": "ACTUAL", "start_date": "2018-11-01", "primary_completion_date": "2021-05-24", "completion_date": "2022-06-13", "conditions": ["Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)", "Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)", "Cohort 3a and 3b: Chondrosarcoma", "Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma", "Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations"], "interventions": ["DRUG: FT-2102", "DRUG: Azacitidine", "BIOLOGICAL: Nivolumab", "DRUG: Gemcitabine and Cisplatin"], "primary_outcomes": [{"measure": "Number of Participants With a Dose Limiting Toxicity (DLT)", "time_frame": "Day 1-28"}, {"measure": "Overall Response Rate (ORR)", "time_frame": "While on treatment"}], "why_stopped": null, "has_results": true, "url": "https://clinicaltrials.gov/study/NCT03684811"}, {"nct_id": "NCT06161974", "title": "Study of Olutasidenib and Temozolomide in HGG", "status": "RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Rigel Pharmaceuticals", "enrollment": 60, "enrollment_type": "ESTIMATED", "start_date": "2025-02-01", "primary_completion_date": "2029-06", "completion_date": "2035-06", "conditions": ["High Grade Glioma", "Astrocytoma", "Astrocytoma, Grade III", "Astrocytoma, Grade IV", "Diffuse Intrinsic Pontine Glioma", "WHO Grade III Glioma", "WHO Grade IV Glioma", "Metastatic Brain Tumor", "Diffuse Midline Glioma, H3 K27M-Mutant", "Thalamus Tumor"], "interventions": ["DRUG: Olutasidenib + TMZ"], "primary_outcomes": [{"measure": "Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)", "time_frame": "Completion of cycle 1 (28 days) for 6-24 patients"}, {"measure": "Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)", "time_frame": "From date of diagnosis until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up 24 months"}, {"measure": "Maximum plasma concentration [Cmax] of Olutasidenib", "time_frame": "From Day 1 of treatment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 24 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT06161974"}, {"nct_id": "NCT07486713", "title": "Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies", "status": "RECRUITING", "phase": ["PHASE4"], "study_type": "INTERVENTIONAL", "sponsor": "Rigel Pharmaceuticals", "enrollment": 16, "enrollment_type": "ESTIMATED", "start_date": "2026-02-23", "primary_completion_date": "2027-04-30", "completion_date": "2027-06-30", "conditions": ["AML (Acute Myeloid Leukemia)", "Glioma", "Cholangiocarcinoma", "Solid Tumor Malignancies"], "interventions": ["DRUG: Olutasidenib", "DRUG: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates"], "primary_outcomes": [{"measure": "Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs", "time_frame": "Up to 96 hours after each probe drug administration."}, {"measure": "Maximum Plasma Concentration (Cmax) of Probe Drugs", "time_frame": "Up to 96 hours after each probe drug administration."}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT07486713"}], "source": {"api": "ClinicalTrials.gov API v2", "url": "https://clinicaltrials.gov/api/v2/studies", "retrieved": "2026-09-19"}}

[saved as work/clinical-trialist/0004-search_trials.json ; cite this path, with an exact quote, as evidence]

{"intervention": "safusidenib", "condition": "glioma", "limit": 25}

{"total_count": 4, "returned": 4, "limit": 25, "trials": [{"nct_id": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "status": "RECRUITING", "phase": ["PHASE3"], "study_type": "INTERVENTIONAL", "sponsor": "Nuvation Bio Inc.", "enrollment": 365, "enrollment_type": "ESTIMATED", "start_date": "2023-06-05", "primary_completion_date": "2028-12-01", "completion_date": "2030-12-01", "conditions": ["Glioma", "Astrocytoma, Grade IV", "IDH1-mutant Glioma", "Astrocytoma, IDH-Mutant, Grade 3", "Astrocytoma, IDH-Mutant, Grade 4", "Astrocytoma, IDH-Mutant, Grade 2", "Oligodendroglioma", "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted"], "interventions": ["DRUG: safusidenib", "DRUG: Placebo"], "primary_outcomes": [{"measure": "Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)", "time_frame": "From participants sign ICF to 30 days after last dose\uff0caverage 2 years"}, {"measure": "Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0", "time_frame": "From randomization until the date of first documented disease progression, average 2 years"}, {"measure": "Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0", "time_frame": "From the first dose of study drug until the date of first documented disease progression, average 18 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT05303519"}, {"nct_id": "NCT07712757", "title": "Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma", "status": "NOT_YET_RECRUITING", "phase": ["PHASE3"], "study_type": "INTERVENTIONAL", "sponsor": "Nuvation Bio Inc.", "enrollment": 140, "enrollment_type": "ESTIMATED", "start_date": "2027-03", "primary_completion_date": "2029-05", "completion_date": "2032-03", "conditions": ["Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation", "Astrocytoma IDH Mutant Grade 2", "Oligodendroglioma", "Oligodendroglioma IDH-mutant and 1p/19q-codeleted", "IDH-mutant Gliomas"], "interventions": ["DRUG: Safusidenib", "DRUG: Placebo"], "primary_outcomes": [{"measure": "Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0", "time_frame": "From the date of randomization until the date of first documented disease progression, approximately 30 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT07712757"}, {"nct_id": "NCT07703436", "title": "Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease", "status": "NOT_YET_RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Nuvation Bio Inc.", "enrollment": 40, "enrollment_type": "ESTIMATED", "start_date": "2027-03", "primary_completion_date": "2030-09", "completion_date": "2032-03", "conditions": ["Grade 2 IDH1-mutant Glioma", "Grade 3 IDH1-mutant Glioma", "Glioma", "IDH1-mutant Glioma", "Oligodendroglioma", "Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted", "Astrocytoma IDH Mutant Grade 3", "Astrocytoma IDH Mutant Grade 2"], "interventions": ["DRUG: Safusidenib"], "primary_outcomes": [{"measure": "Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)", "time_frame": "From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT07703436"}, {"nct_id": "NCT05577416", "title": "A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma", "...[truncated 1324 chars]

{"intervention": "DS-1001b", "condition": "glioma", "limit": 25}

{"total_count": 3, "returned": 3, "limit": 25, "trials": [{"nct_id": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "status": "RECRUITING", "phase": ["PHASE3"], "study_type": "INTERVENTIONAL", "sponsor": "Nuvation Bio Inc.", "enrollment": 365, "enrollment_type": "ESTIMATED", "start_date": "2023-06-05", "primary_completion_date": "2028-12-01", "completion_date": "2030-12-01", "conditions": ["Glioma", "Astrocytoma, Grade IV", "IDH1-mutant Glioma", "Astrocytoma, IDH-Mutant, Grade 3", "Astrocytoma, IDH-Mutant, Grade 4", "Astrocytoma, IDH-Mutant, Grade 2", "Oligodendroglioma", "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted"], "interventions": ["DRUG: safusidenib", "DRUG: Placebo"], "primary_outcomes": [{"measure": "Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)", "time_frame": "From participants sign ICF to 30 days after last dose\uff0caverage 2 years"}, {"measure": "Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0", "time_frame": "From randomization until the date of first documented disease progression, average 2 years"}, {"measure": "Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0", "time_frame": "From the first dose of study drug until the date of first documented disease progression, average 18 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT05303519"}, {"nct_id": "NCT03030066", "title": "Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas", "status": "COMPLETED", "phase": ["PHASE1"], "study_type": "INTERVENTIONAL", "sponsor": "Daiichi Sankyo", "enrollment": 47, "enrollment_type": "ACTUAL", "start_date": "2017-01-19", "primary_completion_date": "2021-01-31", "completion_date": "2026-07-16", "conditions": ["Glioma"], "interventions": ["DRUG: DS-1001b"], "primary_outcomes": [{"measure": "Percentage of participants with dose limiting toxicities", "time_frame": "21 days"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT03030066"}, {"nct_id": "NCT04458272", "title": "A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Daiichi Sankyo Co., Ltd.", "enrollment": 25, "enrollment_type": "ESTIMATED", "start_date": "2020-07-08", "primary_completion_date": "2023-03-10", "completion_date": "2026-08-31", "conditions": ["WHO Grade II Glioma"], "interventions": ["DRUG: DS-1001b"], "primary_outcomes": [{"measure": "Overall response rate (ORR) assessed by Independent Efficacy Review Committee", "time_frame": "Up to 24 months"}, {"measure": "Number of participants with treatment-emergent adverse events (TEAEs) during the study", "time_frame": "Up to 24 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT04458272"}], "source": {"api": "ClinicalTrials.gov API v2", "url": "https://clinicaltrials.gov/api/v2/studies", "retrieved": "2026-09-19"}}

[saved as work/clinical-trialist/0006-search_trials.json ; cite this path, with an exact quote, as evidence]

{"condition": "glioma", "status": "TERMINATED", "limit": 25}

{"total_count": 402, "returned": 25, "limit": 25, "trials": [{"nct_id": "NCT01774253", "title": "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma", "status": "TERMINATED", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Giselle Sholler", "enrollment": 9, "enrollment_type": "ACTUAL", "start_date": "2013-05", "primary_completion_date": "2015-10", "completion_date": "2015-10", "conditions": ["Pontine Glioma"], "interventions": ["DRUG: Vismodegib"], "primary_outcomes": [{"measure": "Number of Days Participants Experienced Progression Free Survival (PFS)", "time_frame": "5 years"}], "why_stopped": "Lack of enrollment and commercial availability of drug", "has_results": true, "url": "https://clinicaltrials.gov/study/NCT01774253"}, {"nct_id": "NCT01430351", "title": "Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy", "status": "TERMINATED", "phase": ["PHASE1"], "study_type": "INTERVENTIONAL", "sponsor": "M.D. Anderson Cancer Center", "enrollment": 144, "enrollment_type": "ACTUAL", "start_date": "2011-09-14", "primary_completion_date": "2025-02-02", "completion_date": "2025-02-02", "conditions": ["Glioblastoma", "Gliosarcoma", "Supratentorial Glioblastoma"], "interventions": ["DRUG: Mefloquine", "DRUG: Memantine Hydrochloride", "DRUG: Metformin Hydrochloride", "DRUG: Temozolomide"], "primary_outcomes": [{"measure": "Incidence of toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0", "time_frame": "During first 28 days"}], "why_stopped": "\\<75 % participant accrual", "has_results": false, "url": "https://clinicaltrials.gov/study/NCT01430351"}, {"nct_id": "NCT01305122", "title": "Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma", "status": "TERMINATED", "phase": ["NA"], "study_type": "INTERVENTIONAL", "sponsor": "Centre Leon Berard", "enrollment": 112, "enrollment_type": "ACTUAL", "start_date": "2011-02", "primary_completion_date": "2018-10-21", "completion_date": "2018-10-21", "conditions": ["OMS Grade II Glioma"], "interventions": ["BEHAVIORAL: neurocognitive tests"], "primary_outcomes": [{"measure": "MoCA test", "time_frame": "36 months"}], "why_stopped": "Recruitment too low", "has_results": false, "url": "https://clinicaltrials.gov/study/NCT01305122"}, {"nct_id": "NCT02025231", "title": "Image Guided Reirradiation of High-grade Glioma", "status": "TERMINATED", "phase": ["PHASE1", "PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Rigshospitalet, Denmark", "enrollment": 31, "enrollment_type": "ACTUAL", "start_date": "2011-12", "primary_completion_date": "2015-04", "completion_date": "2015-04", "conditions": ["Malignant Glioma", "Glioblastoma"], "interventions": ["RADIATION: External beam radiotherapy"], "primary_outcomes": [{"measure": "Toxicity", "time_frame": "One year"}, {"measure": "Diagnostic precision of 18F-FET-PET imaging in recurrent high-grade glioma", "time_frame": "Approximately one to two weeks prior to radiotherapy"}, {"measure": "Time to neurocognitive decline", "time_frame": "Up to one year"}, {"measure": "Time to progression", "time_frame": "Up to one year"}], "why_stopped": "Slow accrual", "has_results": false, "url": "https://clinicaltrials.gov/study/NCT02025231"}, {"nct_id": "NCT03717142", "title": "Feasibility of the LUM Imaging System for Detection of Cancer to the Brain", "status": "TERMINATED", "phase": ["NA"], "study_type": "INTERVENTIONAL", "sponsor": "Lumicell, Inc.", "enrollment": 4, "enrollment_type": "ACTUAL", "start_date": "2019-05-03", "primary_completion_date": "2023-09-13", "completion_date": "2024-06-14", "conditions": ["Low Grade Glioma of Brain", "Glioblastoma", "Metastasis to Brain"], "interventions": ["COMBINATION_PRODUCT: LUM Imaging System"], "primary_outcomes": [{"measure": "Correlation of fluorescenc...[truncated 21119 chars]

{"intervention": "vorasidenib OR ivosidenib OR olutasidenib OR safusidenib OR IDH inhibitor", "condition": "glioma", "status": "TERMINATED", "limit": 25}

{"total_count": 0, "returned": 0, "limit": 25, "trials": [], "source": {"api": "ClinicalTrials.gov API v2", "url": "https://clinicaltrials.gov/api/v2/studies", "retrieved": "2026-09-19"}}

[saved as work/clinical-trialist/0008-search_trials.json ; cite this path, with an exact quote, as evidence]

{"intervention": "vorasidenib OR ivosidenib OR olutasidenib OR safusidenib OR IDH inhibitor", "condition": "glioma", "status": "WITHDRAWN", "limit": 25}

{"total_count": 1, "returned": 1, "limit": 25, "trials": [{"nct_id": "NCT06648473", "title": "Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib", "status": "WITHDRAWN", "phase": ["NA"], "study_type": "INTERVENTIONAL", "sponsor": "Duke University", "enrollment": 0, "enrollment_type": "ACTUAL", "start_date": "2026-01-01", "primary_completion_date": "2027-12-01", "completion_date": "2027-12-01", "conditions": ["Low Grade Glioma of Brain"], "interventions": ["DIAGNOSTIC_TEST: MRI Scan"], "primary_outcomes": [{"measure": "Repeatability", "time_frame": "1 year"}], "why_stopped": "sponsor withdrew funding", "has_results": false, "url": "https://clinicaltrials.gov/study/NCT06648473"}], "source": {"api": "ClinicalTrials.gov API v2", "url": "https://clinicaltrials.gov/api/v2/studies", "retrieved": "2026-09-19"}}

[saved as work/clinical-trialist/0009-search_trials.json ; cite this path, with an exact quote, as evidence]

{"claims": [{"id": "C1", "text": "IDH1 is Ensembl gene ENSG00000138413.", "confidence": "high", "evidence": [{"artifact": "work/target-biologist/0001-search_target.json", "quote": "ENSG00000138413"}]}, {"id": "C2", "text": "Open Targets scores the IDH1-glioma association at 0.6368 (glioblastoma 0.6574, astrocytoma excluding glioblastoma 0.5887, oligodendroglioma 0.5787).", "confidence": "high", "evidence": [{"artifact": "work/target-biologist/0002-target_disease_associations.json", "quote": "0.6368"}]}, {"id": "C3", "text": "Small-molecule tractability is strong: positive features include Approved Drug, Structure with Ligand, High-Quality Ligand and High-Quality Pocket.", "confidence": "high", "evidence": [{"artifact": "work/target-biologist/0003-target_tractability.json", "quote": "High-Quality Ligand"}]}, {"id": "C4", "text": "Antibody tractability is weak: the only positive feature is GO CC high conf, with no approved or clinical antibody evidence.", "confidence": "medium", "evidence": [{"artifact": "work/target-biologist/0003-target_tractability.json", "quote": "GO CC high conf"}]}, {"id": "C5", "text": "Vorasidenib is an approved IDH1/IDH2 inhibitor with glioma indications (astrocytoma, oligodendroglioma, glioma); safusidenib is Phase 3, DS-1001b and IDH305 Phase 2, olutasidenib and ivosidenib approved.", "confidence": "medium", "evidence": [{"artifact": "work/target-biologist/0004-known_drugs.json", "quote": "VORASIDENIB"}]}, {"id": "C6", "text": "One stopped IDH-inhibitor glioma trial was found: NCT06648473 (ivosidenib, MRI imaging study, Phase NA, Duke University), WITHDRAWN with reason 'sponsor withdrew funding', enrollment 0.", "confidence": "medium", "evidence": [{"artifact": "work/clinical-trialist/0009-search_trials.json", "quote": "sponsor withdrew funding"}]}, {"id": "C7", "text": "A search for terminated IDH inhibitor glioma trials returned 0 results.", "confidence": "low", "evidence": [{"artifact": "work/clinical-trialist/0008-search_trials.json"}]}]}

{"accepted": ["C1", "C2", "C3", "C4", "C5", "C6", "C7"], "replaced": [], "total_claims": 7, "warnings": ["claim C2: evidence[0] quote for 'work/target-biologist/0002-target_disease_associations.json' is under 12 characters and would match almost anything", "claim C5: evidence[0] quote for 'work/target-biologist/0004-known_drugs.json' is under 12 characters and would match almost anything", "claim C7: no evidence item carries a quote, so support is a file pointer only"]}

{"claims": [{"id": "C2", "text": "Open Targets scores the IDH1-glioma association at 0.6368.", "confidence": "high", "evidence": [{"artifact": "work/target-biologist/0002-target_disease_associations.json", "quote": "0.6368"}]}, {"id": "C4", "text": "Antibody tractability lists GO CC high conf as a positive feature.", "confidence": "medium", "evidence": [{"artifact": "work/target-biologist/0003-target_tractability.json", "quote": "GO CC high conf"}]}]}

{"accepted": ["C2", "C4"], "replaced": ["C2", "C4"], "total_claims": 7, "warnings": ["claim C2: evidence[0] quote for 'work/target-biologist/0002-target_disease_associations.json' is under 12 characters and would match almost anything"]}

{"condition": "glioma", "intervention": "vorasidenib"}

{"total_count": 14, "returned": 10, "limit": 10, "trials": [{"nct_id": "NCT07469735", "title": "Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma", "status": "NOT_YET_RECRUITING", "phase": ["NA"], "study_type": "INTERVENTIONAL", "sponsor": "Huashan Hospital", "enrollment": 10, "enrollment_type": "ESTIMATED", "start_date": "2026-04-01", "primary_completion_date": "2027-06-30", "completion_date": "2027-12-31", "conditions": ["Glioma", "Diffuse Glioma", "Recurrent Gliomas"], "interventions": ["DRUG: Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma."], "primary_outcomes": [{"measure": "Change in Tumor Metabolic Activity Assessed by 18F-AGX PET", "time_frame": "Up to 12 treatment cycles (approximately 12 months)"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT07469735"}, {"nct_id": "NCT05592743", "title": "Vorasidenib Expanded Access Program", "status": "APPROVED_FOR_MARKETING", "phase": [], "study_type": "EXPANDED_ACCESS", "sponsor": "Servier", "enrollment": null, "enrollment_type": null, "start_date": null, "primary_completion_date": null, "completion_date": null, "conditions": ["Glioma", "Recurrence", "Disease Attributes", "Pathologic Processes", "Neoplasms, Neuroepithelial", "Neuroectodermal Tumors", "Neoplasms, Germ Cell and Embryonal", "Neoplasms by Histologic Type", "Neoplasms", "Neoplasms, Glandular and Epithelial"], "interventions": ["DRUG: Vorasidenib"], "primary_outcomes": [], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT05592743"}, {"nct_id": "NCT04164901", "title": "Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE3"], "study_type": "INTERVENTIONAL", "sponsor": "Institut de Recherches Internationales Servier", "enrollment": 331, "enrollment_type": "ACTUAL", "start_date": "2020-01-05", "primary_completion_date": "2022-09-06", "completion_date": "2028-05", "conditions": ["Grade 2 Glioma", "Residual Glioma", "Recurrent Glioma"], "interventions": ["DRUG: Vorasidenib", "DRUG: Matching Placebo"], "primary_outcomes": [{"measure": "Progression-Free Survival (PFS)", "time_frame": "Up to approximately 30 months"}], "why_stopped": null, "has_results": true, "url": "https://clinicaltrials.gov/study/NCT04164901"}, {"nct_id": "NCT07703436", "title": "Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease", "status": "NOT_YET_RECRUITING", "phase": ["PHASE2"], "study_type": "INTERVENTIONAL", "sponsor": "Nuvation Bio Inc.", "enrollment": 40, "enrollment_type": "ESTIMATED", "start_date": "2027-03", "primary_completion_date": "2030-09", "completion_date": "2032-03", "conditions": ["Grade 2 IDH1-mutant Glioma", "Grade 3 IDH1-mutant Glioma", "Glioma", "IDH1-mutant Glioma", "Oligodendroglioma", "Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted", "Astrocytoma IDH Mutant Grade 3", "Astrocytoma IDH Mutant Grade 2"], "interventions": ["DRUG: Safusidenib"], "primary_outcomes": [{"measure": "Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)", "time_frame": "From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months"}], "why_stopped": null, "has_results": false, "url": "https://clinicaltrials.gov/study/NCT07703436"}, {"nct_id": "NCT06780930", "title": "Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "phase": ["PHASE3"], "study_type": "INTERVENTIONAL", "sponsor": "Servier", "enrollment": 57, "enrollment_type": "ACTUAL",...[truncated 5620 chars]

{"condition": "glioma", "intervention": "ivosidenib OR olutasidenib OR safusidenib OR DS-1001b OR IDH305", "status": "TERMINATED"}

{"total_count": 0, "returned": 0, "limit": 10, "trials": [], "source": {"api": "ClinicalTrials.gov API v2", "url": "https://clinicaltrials.gov/api/v2/studies", "retrieved": "2026-09-19"}}

[saved as work/clinical-trialist/0011-search_trials.json ; cite this path, with an exact quote, as evidence]

{"claims": [{"id": "C7", "text": "A search for terminated trials of ivosidenib, olutasidenib, safusidenib, DS-1001b or IDH305 in glioma returned 0 trials.", "confidence": "medium", "evidence": [{"artifact": "work/clinical-trialist/0011-search_trials.json", "quote": "\"total_count\": 0"}]}, {"id": "C8", "text": "A ClinicalTrials.gov search for vorasidenib in glioma (any status) found 14 trials; the 10 returned had no why-stopped text.", "confidence": "medium", "evidence": [{"artifact": "work/clinical-trialist/0010-search_trials.json", "quote": "\"total_count\": 14"}]}]}

{"accepted": ["C7", "C8"], "replaced": ["C7"], "total_claims": 8, "warnings": []}